McCann Health calls on Piasecki to head region

Share this article:
Marci Piasecki
Marci Piasecki

Marci Piasecki was promoted to regional director, North America, with oversight over all five US professional agencies in McCann Health. Hers is the most senior of a series of personnel moves IPG's McCann Health says it made to bolster the North American operation.

With the promotion, Piasecki, longtime CEO of the Torre Lazur Group and its three professional agencies, takes on two more. Her remit now spans McCann Torre Lazur and McCann Echo Torre Lazur, along with McCann Regan Campbell Ward and McCann RCW Healthcare. McCann Managed Markets, renamed without the “TL,” makes five. 

"I am honored and eager to assume this new level of leadership within McCann Health,” said Marci Piasecki in a statement expected to be released today. “Equally importantly, I am excited for my colleagues who have worked alongside me to provide our network with their expanded responsibilities.”

John Cahill, the company's global CEO, called Piasecki “an extraordinary leader and pillar” of the network who has maintained growth “whatever the business environment,” while attracting and retaining staff and clients. 

Head of North America is a newly created position, the catalyst for which was the regionalization of the US professional units within the McCann Health global network. The move put North America on par with Asia-Pacific, Europe and the leaders in each of those regions.

It follows a rebranding of the units last year designed to align the US agencies more closely with their parent.

Piasecki's ascendance prompted a series of other staff changes. The reins of McCann Torre Lazur, an agency Piasecki led for eight years, were handed to Bill McEllen, whose new title became president of McCann Torre Lazur Group, overseeing McCann Torre Lazur and McCann Echo Torre Lazur. 

Sonja Foster-Storch, formerly managing director of Omnicom's CDM Princeton, was hired to succeed McEllen as president of McCann Echo Torre Lazur, an agency he headed for four years.

Meanwhile, on the RCW side, Maureen Regan remains president of McCann Regan Campbell Ward Group, which consists of McCann Regan Campbell Ward and McCann RCW Healthcare. Brendan Ward took on a science role for the agency and Richard Campbell retained his role as head of planning.

And finally, roster brands at all four agencies will now have access to cost-and-coverage services courtesy of McCann Managed Markets. The shop realigned, moving out of the McCann Torre Lazur Group so its services are more accessible to all US professional shops in the reconfigured North American region. Kim Wishnow-Per was promoted to president of the agency, from managing director.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...